Get the latest news and updates
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
Confirmed Presenting Companies:
Dr. Olin is an Assistant Professor in the Department of Pediatrics, Division of Hematology/Oncology. Dr. Olin graduated from the University of Minnesota, Duluth, in 1995 with a BS in biochemistry and Hydrogeology, a BA in chemistry. After graduating, he worked in industry for 5 years before returning to the U of M to complete his PhD in Veterinary Medicine (Infectious Disease) in 2005. From 2006-2008 Dr. Olin did a postdoctoral fellowship studying the effects of opioids on tuberculosis meningitis, and from 2008-2011 he did a second post doctoral fellowship in brain tumor immunotherapy. Dr. Olin joined the Department of Pediatrics Faculty as an Assistant Professor in 2011. In 2016, Dr. Olin opened a pharmaceutical company OX2 Therapeutics, to raise capital allowing him to develop and test his novel CD200 inhibitor.
Emerging Therapeutics Showcase: OX2 Therapeutics
OX2 Therapeutics was established in 2016 in order to make a transformative impact in the treatment of Primary Brain Tumors.
CD200-Ligand Overpowers CD200, PD-1 And CTLA4 Checkpoints
We discovered the molecular connection between the CD200, PD-1 and CTLA4 check-points. We demonstrated our CD200 peptide ligand induced cytokine production and up-regulates CD80/86 and MHC-II. In addition, the CD200-ligand overpowered CD200 and PD-L1 immunosuppression, downregulated PD-1 on antigen-presenting and T-cells and down-regulated PD-L1 on antigen-presenting cells inhibiting CTLA4 upregulation.
Dr. Rogers brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
Jason Christiansen has served in multiple positions leading the development of new technologies and strategies for their research and diagnostic use. He has served as Head of Assay Development at Roche Sequencing Solutions, providing leadership in initiatives around oncology testing, Dx development, NIPT testing and platform development. Prior to Roche, Jason was VP of Diagnostics at Ignyta, where he led CDx development efforts including an in-house CLIA laboratory and molecular testing R&D group working both internally and externally to drive molecular testing in support of a global clinical trial for entrectinib. Prior to Ignyta, Jason served in multiple senior positions developing new platforms and technologies in NGS, digital pathology and molecular testing so that they could be brought into the clinical laboratory for patient testing and to support drug development.
Emerging Therapeutics Showcase: Boundless Bio, Inc.
Boundless Bio, is a San Diego based company discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.
Targeting Extrachromosomal DNA (ecDNA), A New Approach To Targeting Cancers With High Copy Number Amplification
Cancers driven by genetic amplification are dominated by poor prognosis and have been a problematic target for therapeutics to date. However, the recent elucidation of ecDNA as a mechanism for supporting high copy number cancers and driving tumor heterogeneity has also provided insight on previous therapeutic failures and new avenues for potential treatment. Using multiple laboratory approaches, new ecDNA specific targets can be identified to precisely select patient groups and provide new treatments.
Dr. Wang is the CEO of Refuge, a company he co-founded following nearly a decade of life science investment banking experience. He most recently served as director of healthcare investment banking at Barclays Capital, where he served as strategic financial advisor and helped raised capital for companies in the healthcare industry. Dr. Wang, a cancer survivor who is passionate about bringing forth “smarter” medicines that will transform cancer care, earned a B.S. in Applied Physics from Columbia University, an MBA from Columbia Business School, and a Ph.D. in Electrical Engineering from Princeton University.
Emerging Therapeutics Showcase: Refuge Biotechnologies
Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body.
Designing Intelligent Cell Therapies To Fight Cancer
Refuge Biotechnologies leverages synthetic biology technologies known as CRISPR Interference/activation to develop therapeutic cells programmed to make decisions inside a patient’s body.